Nature Communications (Oct 2023)

Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia

  • Hope Mumme,
  • Beena E. Thomas,
  • Swati S. Bhasin,
  • Upaasana Krishnan,
  • Bhakti Dwivedi,
  • Pruthvi Perumalla,
  • Debasree Sarkar,
  • Gulay B. Ulukaya,
  • Himalee S. Sabnis,
  • Sunita I. Park,
  • Deborah DeRyckere,
  • Sunil S. Raikar,
  • Melinda Pauly,
  • Ryan J. Summers,
  • Sharon M. Castellino,
  • Daniel S. Wechsler,
  • Christopher C. Porter,
  • Douglas K. Graham,
  • Manoj Bhasin

DOI
https://doi.org/10.1038/s41467-023-41994-0
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 20

Abstract

Read online

Abstract Acute myeloid leukemia (AML) microenvironment exhibits cellular and molecular differences among various subtypes. Here, we utilize single-cell RNA sequencing (scRNA-seq) to analyze pediatric AML bone marrow (BM) samples from diagnosis (Dx), end of induction (EOI), and relapse timepoints. Analysis of Dx, EOI scRNA-seq, and TARGET AML RNA-seq datasets reveals an AML blasts-associated 7-gene signature (CLEC11A, PRAME, AZU1, NREP, ARMH1, C1QBP, TRH), which we validate on independent datasets. The analysis reveals distinct clusters of Dx relapse- and continuous complete remission (CCR)-associated AML-blasts with differential expression of genes associated with survival. At Dx, relapse-associated samples have more exhausted T cells while CCR-associated samples have more inflammatory M1 macrophages. Post-therapy EOI residual blasts overexpress fatty acid oxidation, tumor growth, and stemness genes. Also, a post-therapy T-cell cluster associated with relapse samples exhibits downregulation of MHC Class I and T-cell regulatory genes. Altogether, this study deeply characterizes pediatric AML relapse- and CCR-associated samples to provide insights into the BM microenvironment landscape.